Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Product/Service, Funding

EU Malaria Fund Enters Post-investment Period


On 30 September, the EU Malaria Fund (EUMF) concluded its investment activities at a high-level online event by finalizing its investments into four innovative companies active in malaria R&D. The EUMF has successfully expanded the pipeline of malaria R&D by funding nine promising and innovative malaria projects, covering treatments, vaccines, and diagnostics.

The COVID-19 pandemic has changed the game and led to the deployment of four EMA-approved, safe, and effective vaccines within less than 12 months. With this novel need to develop a large project on a now proven technology platform, the EUMF has successfully accomplished its mission earlier than expected. The EUMF will now enter its post-investment period.

The EUMF is grateful to the European Commission and the European Investment Bank (EIB), the major contributors to the Fund through the InnovFin EU programme funded by EU Horizon 2020 and the European Fund of Strategic Investments.

Other investors and supporters include the Investitionsbank Berlin, the Bill & Melinda Gates Foundation, Fondazione Monte Dei Paschi Di Siena, Jacques und Gloria Gossweiler Stiftung, Invethos AG, FINDdx, and Novartis AG. The fund was initiated by kENUP Foundation in cooperation with EIB and is managed by IBB Group Berlin.

The investments would not have been possible without the excellent work of the Funds Scientific Advisory Council and the Investment Decision Committee.

On 26 July, BioNTech SE announced the start of its Malaria project which aims at the development of a safe and highly effective malaria vaccine and the implementation of sustainable vaccine supply solutions on the African continent. The program was initiated by kENUP Foundation. Additional such programmes are currently being conceived and could cover other infectious diseases, such as tuberculosis and HIV.

Pedro Alonso, Director of the World Health Organization's Global Malaria Programme, states: "The EU Malaria Fund is a great example how innovative new instruments can ultimately lead to impact. Malaria is the biggest killer of mankind. It affects the poorest and contributes to keeping them in poverty. I would like to thank everyone involved in the EU Malaria Fund project for their contribution to fighting malaria."

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth: "Malaria is one of the most challenging diseases to beat and all efforts to find new vaccines or preventive means are important. For decades the European Union's research and innovation programmes provided support to contribute to the global research agenda for malaria and we are committed to continue these efforts."

Werner Hoyer, President of the European Investment Bank: "Malaria kills more than 1000 people each day ? most of them children. Every step in the fight against the disease is welcome and much needed. Thanks to the successful work of the EU Malaria Fund, which financed nine promising projects, we significantly increased our chances to find new medications, diagnostics and vaccines. I am proud that the EIB is part of this effort."

The video recording and more information can be found at https://www.controlmalaria.eu/news#conclusion


These press releases may also interest you

at 01:15
QIAGEN N.V. announced today the CE marking of its QuantiFERON® SARS-CoV-2 assay that measures T-cell responses to SARS-CoV-2 and aids in the assessment of immunity in individuals who have received COVID-19 vaccination. COVID-19 vaccines stimulate...

at 01:15
-- UCB to partner with Novartis on development of UCB0599 with an opt-in to develop UCB7853, two innovative and potentially disease-modifying investigational assets in Parkinson's disease -- UCB will receive upfront payment of US$150 million and is...

at 01:00
Dr. Karl Pankratz performed robot-assisted total knee replacement surgery today at Covenant High Plains Surgery Center (CHPSC), expanding the program to many more West Texas patients seeking high-quality, cost-effective outpatient knee replacement...

1 déc 2021
Pulmotect, Inc., a clinical-stage biotechnology company, announced results from the second of two Phase 2 clinical trials undertaken in the United States with the support of the U.S. Department of Defense (DOD) to evaluate PUL-042 against COVID-19....

1 déc 2021
Peng Liyuan, wife of Chinese President Xi Jinping and the World Health Organization (WHO)'s goodwill ambassador for tuberculosis and HIV/AIDS, sent a video message to the students of the Linfen Red Ribbon School in north China's Shanxi Province at an...

1 déc 2021
On the occasion of the 34th World AIDS Day Wednesday, Peng Liyuan, wife of Chinese President Xi Jinping, sent her best wishes to students in the Linfen Red Ribbon School in north China's Shanxi Province, the only facility set up in the country...



News published on 7 october 2021 at 04:05 and distributed by: